Novel therapeutic targets in rheumatoid arthritis

Trends in Pharmacological Sciences

Volumn 36, Issue 4, 2015, Pages 189-195

  Koenders, Marije I ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

IL 17; JAK; rheumatoid arthritis; Th17; therapeutic targets

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; JANUS KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; TH17 CELL; TRENDS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; JANUS KINASES; TH17 CELLS;

EID: 84939958120     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.02.001     Document Type: Review

References (82)

1. L. Klareskog Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis Curr. Opin. Rheumatol. 26 2014 72 79
2. L. Moreland A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial Arthritis Rheum. 64 2012 2824 2835
3. M. Mertens, and J.A. Singh Anakinra for rheumatoid arthritis Cochrane Database Syst. Rev. 2009 CD005121
4. A.A. Jesus, and R. Goldbach-Mansky IL-1 blockade in autoinflammatory syndromes Annu. Rev. Med. 65 2014 223 244
5. J.S. Smolen Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997
6. J.S. Smolen EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann. Rheum. Dis. 73 2014 492 509
7. J.L. Nam Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis Ann. Rheum. Dis. 73 2014 516 528
8. J.R. O'Dell Therapies for active rheumatoid arthritis after methotrexate failure N. Engl. J. Med. 369 2013 307 318
9. K. Shuai, and B. Liu Regulation of JAK-STAT signalling in the immune system Nat. Rev. Immunol. 3 2003 900 911
10. E. Salgado Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis Ann. Rheum. Dis. 73 2014 871 882
11. R.F. van Vollenhoven Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N. Engl. J. Med. 367 2012 508 519
12. G.R. Burmester Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 2013 451 460
13. E.B. Lee Tofacitinib versus methotrexate in rheumatoid arthritis N. Engl. J. Med. 370 2014 2377 2386
14. S. Onuora Rheumatoid arthritis: can tofacitinib be used as first-line monotherapy for RA? Nat. Rev. Rheumatol. 10 2014 443
15. D.L. Boyle The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis Ann. Rheum. Dis. 2014 Published online November 14, 2014. http://dx.doi.org/10.1136/annrheumdis-2014-206028
16. S. Kubo The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells Ann. Rheum. Dis. 73 2014 2192 2198
17. S. Cohen Analysis of infections and all-cause mortality in phase ii, phase iii, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis Arthritis Rheumatol. 66 2014 2924 2937
18. S. Verstovsek A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N. Engl. J. Med. 366 2012 799 807
19. W. Williams A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA) Arthritis Rheumatol. 58 2008 S431
20. E.C. Keystone Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate Ann. Rheum. Dis. 2014 Published online November 27, 2014. http://dx.doi.org/10.1136/annrheumdis-2014-206478
21. C. Tasset The JAK1-selective inhibitor GLPG0634 is safe and rapidly reduces disease activity in patients with moderate to severe rheumatoid arthritis; results of a 4-week dose ranging study Arthritis Rheumatol. 65 2013 S1018
22. M. Luchi A randomized, dose-ranging, placebo-controlled, 84-day study of INCB039110, a selective Janus kinase-1 inhibitor, in patients with active rheumatoid arthritis Arthritis Rheumatol. 65 2013 S765 S766
23. R.M. Fleischmann A double-blind, placebo-controlled, randomized, 12-week, dose-ranging study of VX-509 (decernotinib), an oral selective Janus kinase 3 (JAK3) inhibitor, as monotherapy in patients with active rheumatoid arthritis Arthritis Rheumatol. 67 2015 334 343
24. L.E. Harrington Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat. Immunol. 6 2005 1123 1132
25. H. Park A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat. Immunol. 6 2005 1133 1141
26. E. Bettelli Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
27. N. Manel The differentiation of human Th-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγT Nat. Immunol. 9 2008 641 649
28. S.L. Gaffen Structure and signaling in the IL-17 receptor family Nat. Rev. Immunol. 9 2009 556 567
29. N.J. Gullick Enhanced and persistent levels of interleukin (IL)-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis Clin. Exp. Immunol. 174 2013 292 301
30. D.Y. Chen Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy Arthritis Res. Ther. 13 2011 R126
31. S. Alzabin Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway Ann. Rheum. Dis. 71 2012 1741 1748
32. E. Lubberts Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheumatol. 50 2004 650 659
33. M.I. Koenders Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1 Am. J. Pathol. 167 2005 141 149
34. W. Hueber Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci. Transl. Med. 2 2010 52ra72
35. M.C. Genovese Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Ann. Rheum. Dis. 72 2013 863 869
36. M.C. Genovese One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study J. Rheumatol. 41 2014 414 421
37. D. Baeten Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial Lancet 382 2013 1705 1713
38. I.B. McInnes Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial Ann. Rheum. Dis. 73 2014 349 356
39. R.G. Langley Secukinumab in plaque psoriasis: results of two phase 3 trials N. Engl. J. Med. 371 2014 326 338
40. M.C. Genovese LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis Arthritis Rheumatol. 62 2010 929 939
41. M.C. Genovese A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors Arthritis Rheumatol. 66 2014 1693 1704
42. K.A. Papp Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N. Engl. J. Med. 366 2012 1181 1189
43. P.J. Mease Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis N. Engl. J. Med. 370 2014 2295 2306
44. K. Pavelka A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate Arthritis Rheumatol. 64 2012 S362
45. D.A. Martin A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis Arthritis Res. Ther. 15 2013 R164
46. M.I. Koenders T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization Arthritis Rheumatol. 64 2012 1762 1770
47. J. Yang Targeting Th17 cells in autoimmune diseases Trends Pharmacol. Sci. 35 2014 493 500
48. K. Reich One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis Br. J. Dermatol. 170 2014 435 444
49. I.B. McInnes Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet 382 2013 780 789
50. K. Reich A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis N. Engl. J. Med. 365 2011 1586 1596
51. S. Krausz A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis Arthritis Rheumatol. 64 2012 1750 1755
52. L.A. Solt Suppression of Th17 differentiation and autoimmunity by a synthetic ROR ligand Nature 472 2011 491 494
53. S. Fujita-Sato Structural basis of digoxin that antagonizes ROR γt receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production J. Biol. Chem. 286 2011 31409 31417
54. J.R. Huh Digoxin and its derivatives suppress Th17 cell differentiation by antagonizing RORγt activity Nature 472 2011 486 490
55. T. Korn IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells Nature 448 2007 484 487
56. R.J. Marijnissen Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis Arthritis Rheumatol. 66 2014 886 895
57. H. Ikeuchi Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine Arthritis Rheumatol. 52 2005 1037 1046
58. J. Leipe Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis Ann. Rheum. Dis. 70 2011 1453 1457
59. K.W. Kim Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts Arthritis Rheumatol. 64 2012 1015 1023
60. R.J. Marijnissen Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation Arthritis Rheumatol. 63 2011 2939 2948
61. Y. Zheng Interleukin-22, a Th17 cytokine, mediated IL-23-induced dermal inflammation and acanthosis Nature 445 2007 648 651
62. S.V. Kotenko Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity J. Immunol. 166 2001 7096 7103
63. L. Dumoutier Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22 J. Immunol. 166 2001 7090 7095
64. L. Codam RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation Nat. Immunol. 12 2011 560 567
65. M. El-Behi The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF Nat. Immunol. 12 2011 568 575
66. G.R. Burmester Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis Ann. Rheum. Dis. 72 2013 1445 1452
67. Y. Saito AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation Arthritis Rheumatol. 66 2014 1185 1194
68. M. Samson Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis Arthritis Rheumatol. 64 2012 2499 2503
69. K. Maeshima The JAK inhibitor Tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells Arthritis Rheumatol. 64 2012 1790 1798
70. J. Mélet Rituximab-induced T cell depletion in patients with rheumatoid arthritis Arthritis Rheumatol. 65 2013 2783 2790
71. F.L. Van de Veerdonk The anti-CD20 antibody rituximab reduces the Th17 cell response Arthritis Rheumatol. 63 2011 1507 1516
72. M.C. Genovese Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheumatol. 50 2004 1412 1419
73. M. Weinblatt Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial Ann. Rheum. Dis. 66 2007 228 234
74. M.I. Koenders Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis Arthritis Rheumatol. 63 2011 2329 2339
75. C. Plater-Zyberk Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model Ann. Rheum. Dis. 68 2009 721 728
76. M. Khory Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes Arthritis Rheumatol. 58 2008 2356 2367
77. Y. Zhang Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model Int. Immunopharmacol. 15 2013 199 205
78. Y. Vugmeyster Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice Int. Immunopharmacol. 18 2014 225 227
79. S. Reardon Microbiome therapy gains market traction Nature 509 2014 269 270
80. J.U. Scher Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis Elife 2 2014 e01202
81. S. Abdollahi-Roodsaz Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis J. Clin. Invest. 118 2008 205 216
82. S.G. De Aquino Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL-1-driven Th17 response J. Immunol. 192 2014 4103 4111